Dr. Reddy’s Laboratories on Wednesday said the Central Drugs Standard Control Organisation (CDSCO), under the Drugs Controller General of India (DCGI), have approved Zytorvi (toripalimab) in combination with cisplatin and paclitaxel.
The approval is for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).
M.V. Ramana, Chief Executive Officer, Global Generics, Dr. Reddy’s Laboratories said, “As we continue to build our oncology portfolio, our focus remains on bringing meaningful advances and expanding access to innovative treatment options.”
Dr. Reddy’s entered into a licensing and commercialization agreement with Junshi Biosciences in 2023 for toripalimab across 21 countries.
Globally, Toripalimab is approved by regulatory authorities including the US Food and Drug Administration (USFDA), the European Medicines Agency (EMA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA), according to a release.
Published on October 21, 2026
